The European Medicines Agency’s Icotyde product page states that Icotyde received a marketing authorisation valid throughout the EU on 18 September 2026, with Janssen-Cilag International as marketing authorisation holder, according to the EMA overview opened for this pack. Johnson & Johnson’s 21 September company announcement (via BioSpace / GlobeNewswire wire copy) publicised the Commission approval; the date used for the authorisation itself is the EMA “Marketing authorisation issued: 18/09/2026” line. EMA also records a CHMP opinion adopted 23 July 2026 — a prior step, not the Commission decision date.
Indication as EMA states it: Icotyde is for treating moderate-to-severe plaque psoriasis in adults who need systemic treatment and in adolescents from 12 years of age weighing at least 40 kg who need such treatment. The active substance is icotrokinra (listed as icotrokinra hydrochloride). EMA describes the medicine as a tablet taken once a day after waking on an empty stomach, with no food for at least 30 minutes after the dose; if treatment has not worked well enough after 24 weeks, the doctor may consider stopping — SmPC-level detail via EMA overview.
Mechanism and evidence as EMA summarises: icotrokinra blocks the receptor for interleukin-23, a protein involved in plaque-psoriasis inflammation. Four main studies involving around 2,500 patients from 12 years of age showed effectiveness. EMA states that in three of those studies, after 16 weeks, between 50% and 57% of patients on Icotyde achieved PASI 90 versus 1% to 4% on placebo, and between 65% and 71% achieved an IGA score of 0 or 1 versus 8% to 11% on placebo — ranges from the EMA overview, not a single trial table opened here. A fourth study involved difficult-to-treat sites (scalp, genital region, hands and feet). J&J materials cite head-to-head ICONIC-ADVANCE results versus deucravacitinib and “first targeted oral peptide” framing; those are company claims — efficacy floors below follow EMA wording.
Safety as EMA states: the most common side effect (around 1 in 100 people) is fungal infections; Icotyde must not be used in people with important active infections such as active tuberculosis. The medicine is under additional monitoring. EMA’s benefit-risk conclusion — benefits greater than risks — is the Agency’s authorisation rationale.
ATC and monitoring details from the opened EMA page: pharmacotherapeutic group immunosuppressants; ATC code L04AC28; EMA product number EMEA/H/C/006730; additional monitoring applies. “First oral medicine targeting interleukin-23 receptor” language appears in prior EMA CHMP communication and company materials; the authorisation fact for this pack is the 18 September EU marketing authorisation on the Icotyde EPAR page.
What to watch without mood: national pricing and reimbursement decisions after EU authorisation; uptake versus injectable IL-23 and oral TYK2 options; any post-authorisation safety signals under additional monitoring; and J&J/Protagonist commercial rollout timing outside the opened EMA page.
Floor: EMA — Icotyde (icotrokinra) EU MA issued 18 Sep 2026 (Janssen-Cilag International); adults + adolescents ≥12 y / ≥40 kg, moderate-to-severe plaque psoriasis needing systemic therapy; once-daily oral IL-23R antagonist; ~2,500-patient programme; PASI 90 / IGA 0/1 ranges as EMA overview; additional monitoring. J&J 21 Sep announcement = publicity colour.